BURLINGTON, Mass. - 908 Devices Inc. (NASDAQ:MASS) appointed Kola Otitoju as Chief Business & Strategy Officer, a newly created executive position, according to a press release statement.
Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as the company expands its market presence across public health, safety, and defense-tech applications.
Otitoju brings over 25 years of executive experience in strategy, business development, and P&L management across medical technology, life sciences, and industrial sectors. He most recently served as Senior Vice President of Strategy & Business Development at Repligen Corporation, where he led global corporate strategy and executed more than 15 M&A transactions and strategic partnerships over six years.
Prior to Repligen, Otitoju held senior strategy and business development roles at Candela Medical, Baxter International, and GE Healthcare, where he served as Managing Director and Head of Business Development. He spent eight years in investment banking at Credit Suisse and Bank of America Securities, advising on M&A transactions across healthcare, industrials, and technology sectors.
The Compensation Committee of 908 Devices’ Board of Directors granted Otitoju 110,193 restricted stock units and options to purchase 146,789 shares of common stock today. The awards were granted as a material inducement to his employment under the 908 Devices Inc. 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest equally over three years on May 1, 2027, May 1, 2028, and May 1, 2029. The stock options have an exercise price of $7.26 per share, equal to the closing price on the grant date, and vest over three years.The timing of Otitoju’s appointment comes as 908 Devices stock has delivered a 52% return over the past year, though the company remains unprofitable with a loss of $0.93 per share over the last twelve months. The company maintains a solid balance sheet, holding more cash than debt, according to InvestingPro analysis, which currently indicates the stock may be undervalued based on its Fair Value assessment.
908 Devices manufactures handheld devices for chemical analysis used in health, safety, and defense applications. For investors seeking deeper insights, InvestingPro offers access to over 6 additional ProTips for MASS, along with comprehensive Pro Research Reports covering more than 1,400 US equities.
In other recent news, 908 Devices Inc. reported impressive financial results for the fourth quarter of 2025. The company achieved earnings per share (EPS) of $0.10, which was a significant 225% positive surprise compared to the forecasted EPS of -$0.08. Additionally, 908 Devices reported revenue of $17.4 million, exceeding the expected $15.84 million by 9.85%. These results highlight the company’s robust growth and strong financial performance.
Furthermore, Stifel has reiterated its Buy rating for 908 Devices with a price target of $8.00. Stifel’s analysis points out that while the company demonstrated solid growth and execution on operational priorities, its gross margins were slightly below expectations. The firm also noted that U.S. policy decisions and macro-level developments could influence product demand for 908 Devices. These developments reflect a positive outlook for the company, according to Stifel’s assessment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.